Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 38

1.

Stimulants and cardiovascular events in youth with attention-deficit/hyperactivity disorder.

Olfson M, Huang C, Gerhard T, Winterstein AG, Crystal S, Allison PD, Marcus SC.

J Am Acad Child Adolesc Psychiatry. 2012 Feb;51(2):147-56. doi: 10.1016/j.jaac.2011.11.008. Epub 2011 Dec 20.

2.

Do prescription stimulants increase the risk of adverse cardiovascular events?: A systematic review.

Westover AN, Halm EA.

BMC Cardiovasc Disord. 2012 Jun 9;12:41. doi: 10.1186/1471-2261-12-41. Review.

3.

Risk of serious cardiovascular problems with medications for attention-deficit hyperactivity disorder.

Martinez-Raga J, Knecht C, Szerman N, Martinez MI.

CNS Drugs. 2013 Jan;27(1):15-30. doi: 10.1007/s40263-012-0019-9. Review.

PMID:
23160939
4.

Attention-deficit/hyperactivity disorder, stimulant therapy, and the patient with congenital heart disease: evidence and reason.

Batra AS, Alexander ME, Silka MJ.

Pediatr Cardiol. 2012 Mar;33(3):394-401. doi: 10.1007/s00246-012-0162-6. Review.

PMID:
22298228
5.

An update on central nervous system stimulant formulations in children and adolescents with attention-deficit/hyperactivity disorder.

Chavez B, Sopko MA Jr, Ehret MJ, Paulino RE, Goldberg KR, Angstadt K, Bogart GT.

Ann Pharmacother. 2009 Jun;43(6):1084-95. doi: 10.1345/aph.1L523. Epub 2009 May 26. Review.

PMID:
19470858
6.

Managing stimulant medication for attention-deficit/hyperactivity disorder.

Wender EH.

Pediatr Rev. 2001 Jun;22(6):183-90. Review. No abstract available. Erratum in: Pediatr Rev 2001 Sep;22(9):292.

PMID:
11389305
7.

Priapism associated with the use of stimulant medications and atomoxetine for attention-deficit/hyperactivity disorder in children.

Eiland LS, Bell EA, Erramouspe J.

Ann Pharmacother. 2014 Oct;48(10):1350-5. doi: 10.1177/1060028014541791. Epub 2014 Jun 30. Review.

PMID:
24982313
8.

Current pharmacotherapy of attention deficit hyperactivity disorder.

Reddy DS.

Drugs Today (Barc). 2013 Oct;49(10):647-65. doi: 10.1358/dot.2013.49.10.2008996. Review.

PMID:
24191257
9.

Neuroendocrine responses to methylphenidate and d-amphetamine: applications to attention-deficit disorder.

Lurie S, O'Quinn A.

J Neuropsychiatry Clin Neurosci. 1991 Winter;3(1):41-50. Review.

PMID:
7580171
10.

Cardiovascular effects of methylphenidate, amphetamines and atomoxetine in the treatment of attention-deficit hyperactivity disorder.

Stiefel G, Besag FM.

Drug Saf. 2010 Oct 1;33(10):821-42. doi: 10.2165/11536380-000000000-00000. Review.

PMID:
20812768
11.

Cardiovascular safety of stimulants in children: findings from recent population-based cohort studies.

Winterstein AG.

Curr Psychiatry Rep. 2013 Aug;15(8):379. doi: 10.1007/s11920-013-0379-y. Review.

PMID:
23913135
12.

Safety of stimulant treatment in attention deficit hyperactivity disorder: Part I.

Merkel RL Jr, Kuchibhatla A.

Expert Opin Drug Saf. 2009 Nov;8(6):655-68. doi: 10.1517/14740330903279956. Review.

PMID:
19785509
13.

Evolution of the treatment of attention-deficit/hyperactivity disorder in children: a review.

Findling RL.

Clin Ther. 2008 May;30(5):942-57. doi: 10.1016/j.clinthera.2008.05.006. Review.

PMID:
18555941
14.
15.

Medications for adolescents with attention-deficit/hyperactivity disorder.

Soileau EJ Jr.

Adolesc Med State Art Rev. 2008 Aug;19(2):254-67, viii-ix. Review.

PMID:
18822831
16.

Amfetamine and methylphenidate medications for attention-deficit/hyperactivity disorder: complementary treatment options.

Hodgkins P, Shaw M, Coghill D, Hechtman L.

Eur Child Adolesc Psychiatry. 2012 Sep;21(9):477-92. doi: 10.1007/s00787-012-0286-5. Epub 2012 Jul 5. Review.

17.

Pharmacological management of attention-deficit hyperactivity disorder.

Reeves G, Schweitzer J.

Expert Opin Pharmacother. 2004 Jun;5(6):1313-20. Review.

PMID:
15163276
18.

Assessment of potential cardiovascular risks of methylphenidate in comparison with sibutramine: do we need a SCOUT (trial)?

Antel J, Albayrak Ö, Heusch G, Banaschewski T, Hebebrand J.

Eur Arch Psychiatry Clin Neurosci. 2015 Apr;265(3):233-47. doi: 10.1007/s00406-014-0522-8. Epub 2014 Aug 23. Review.

PMID:
25149468
19.

Managing stimulant medication for attention-deficit/hyperactivity disorder: an update.

Wender EH.

Pediatr Rev. 2002 Jul;23(7):234-6. Review. No abstract available.

PMID:
12093933
20.

Attention deficit hyperactivity disorder in adults.

Rösler M, Casas M, Konofal E, Buitelaar J.

World J Biol Psychiatry. 2010 Aug;11(5):684-98. doi: 10.3109/15622975.2010.483249. Review.

PMID:
20521876
Items per page

Supplemental Content

Write to the Help Desk